(Q39163578)

English

The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets

scientific article published on 17 April 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Sharon R. Lewin

11

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

object named as

Michael Roche

15

0 references

Jacqueline K Flynn

object named as

Jacqueline K Flynn

1

0 references

2

object named as

Geza Paukovics

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

author name string

Miranda S Moore

3

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Anne Ellett

4

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Renee Duncan

6

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Hamid Salimi

7

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Becky Jubb

8

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Mike Westby

9

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Damian F J Purcell

10

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Melissa J Churchill

13

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Paul R Gorry

14

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

language of work or name

0 references

publication date

17 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

442

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

51-58

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Phenotype and function of human T lymphocyte subsets: consensus and issues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

11-color, 13-parameter flow cytometry: identification of human naive T cells by phenotype, function, and T-cell receptor diversity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

The plasma membrane as a combat zone in the HIV battlefield

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Coreceptors and HIV-1 pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Interaction of small molecule inhibitors of HIV-1 entry with CCR5.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Broad usage spectrum of G protein-coupled receptors as coreceptors by primary isolates of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Entry inhibitors in the treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2013.03.026

7 January 2021

Identifiers

10.1016/J.VIROL.2013.03.026

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39163578&oldid=1896627995"